{"id":"effexor-venlafaxine","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Nausea"},{"rate":"20-25","effect":"Headache"},{"rate":"15-20","effect":"Dizziness"},{"rate":"15-20","effect":"Insomnia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Sweating"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Hypertension"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, thereby prolonging their action in the synapse. At lower doses it preferentially inhibits serotonin reuptake, while at higher doses it also significantly inhibits norepinephrine reuptake. This dual mechanism is thought to enhance mood regulation and reduce anxiety and depressive symptoms.","oneSentence":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:10.975Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT00834964","phase":"PHASE1","title":"Venlafaxine 25 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-12","conditions":"Healthy","enrollment":30},{"nctId":"NCT00834249","phase":"PHASE1","title":"Venlafaxine 25 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-12","conditions":"Healthy","enrollment":18},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT03588572","phase":"NA","title":"The Effect of Venlafaxine on Language Function in Patients With Subcortical Aphasia: A fMRI Study","status":"COMPLETED","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2018-08-01","conditions":"Subcortical Aphasia, Ischemic Stroke","enrollment":43},{"nctId":"NCT02637193","phase":"PHASE1","title":"A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2015-12","conditions":"Healthy Subjects","enrollment":54},{"nctId":"NCT04229602","phase":"NA","title":"Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-01-02","conditions":"Bioequivalence Study","enrollment":28},{"nctId":"NCT02590185","phase":"NA","title":"MetAbolism vaRiability of VEnLafaxine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Major Depressive Disorders","enrollment":205},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT01011751","phase":"PHASE3","title":"Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-04","conditions":"Adenocarcinoma, Prostate","enrollment":311},{"nctId":"NCT01571453","phase":"PHASE3","title":"Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-05","conditions":"Major Depressive Disorder","enrollment":437},{"nctId":"NCT01418209","phase":"NA","title":"MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11","conditions":"Hot Flashes, Menopause, Vasomotor Disturbance","enrollment":339},{"nctId":"NCT00839423","phase":"PHASE2","title":"Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2006-08","conditions":"Major Depressive Disorder","enrollment":426},{"nctId":"NCT00474708","phase":"PHASE4","title":"Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Major Depressive Disorder","enrollment":1151},{"nctId":"NCT01418625","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01418612","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01282814","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT01282801","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT01260896","phase":"PHASE1","title":"Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00871364","phase":"PHASE1","title":"A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-04","conditions":"Healthy","enrollment":30},{"nctId":"NCT00046020","phase":"PHASE4","title":"Study Evaluating Venlafaxine ER in Recurrent Depression","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-08","conditions":"Depressive Disorder, Major, Recurrence","enrollment":1096},{"nctId":"NCT00546494","phase":"PHASE4","title":"Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-02","conditions":"Depression","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Effexor® (Venlafaxine)","genericName":"Effexor® (Venlafaxine)","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}